FILAMENT HEALTH ANNOUNCES NEW UNITED STATES PATENT ISSUANCES

Filament’s industry-leading IP portfolio now consists of ten patents for methods of extracting and standardizing natural psychedelic compounds

VANCOUVER, BC, November 30, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced that it has secured two new patents for the extraction and standardization of natural psilocybin and related psychedelic compounds. Filament’s latest patents were granted by the United States Patent and Trademark Office (USPTO) and describe a technology for transforming variable psychedelic raw materials into standardized pharmaceutical-grade drug candidates.

“When Filament was founded, conventional wisdom held that it was impossible to produce stable psilocin,” said Taran Gray, Director of Intellectual Property. “We have since obtained patent protection for the successful production of psilocin at all stages of manufacturing: from extraction to purification to standardization and beyond. For example, our latest granted patents relating to the non-ingestive administration are demonstrable proof of our team’s talent for innovation The fact that we have never seen a patent application refused, compared to the industry average of a success rate of less than 50 %, is an additional validation of this talent.”

Filament has developed innovative technology to extract and standardize stable doses of natural compounds from magic mushrooms. On August 3, 2021, Filament was awarded the first-ever patent for the extraction and standardization of natural psilocybin. Since then, the Company has been granted a total of five patents by the USPTO and five by the Canadian Intellectual Property Office.

ON FILAMENT HEALTH (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS)
Filament health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally derived psychedelic drugs can improve the lives of many people, and our mission is to get them into the hands of everyone who needs them as soon as possible. Filament’s proprietary intellectual property platform enables the discovery, development and delivery of natural psychedelic drugs. We are leading the way with the very first natural psychedelic drug candidates.

Learn more about www.filament.health and on Twitter, instagram and LinkedIn.

FORWARD-LOOKING INFORMATION
Certain statements and information contained herein may constitute “forward-looking statements” and “forward-looking information”, respectively, under Canadian securities laws. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “expect”, “anticipate”, “continue”, “estimate”, “may”, “will”, “should”. “, “believe”, “intends”, “forecasts”, “plans”, “directions” and similar expressions are intended to identify forward-looking statements or information. Forward-looking statements are not historical facts, but reflect Filament’s management’s current expectations regarding future results or events and are based on information currently available to it. Certain important factors and assumptions were applied in providing these forward-looking statements. The forward-looking statements discussed in this press release may include, but are not limited to, information regarding the impact of the patent on the Company’s business and the Company’s ability to obtain future patents. Forward-looking statements regarding the Company are based on Company estimates and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or Filament’s achievements are materially different from those expressed or implied by such forward-looking statements or forward-looking information, including the status of patent applications and the ability to obtain patents. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Filament will not update any forward-looking statements or forward-looking information that is incorporated by reference herein, except as required by applicable securities laws.

THE SOURCE Filament Health Corp.

© Canada Newswire, source Canada Newswire English